SCNI
Scinai Immunotherapeutics Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Scinai Immunotherapeutics Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
No thesis.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
—
No peers for Scinai Immunotherapeutics Ltd. yet.
No peers for Scinai Immunotherapeutics Ltd. yet.
Annual filing, covered
20-F parsed · Apr 1 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Apr 1 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Expected move
No implied move.
—
Scinai Immunotherapeutics Ltd.
0.47
—
| Manager | Value | % base | |
|---|---|---|---|
| Citadel | $15,726 | 33.10% | new |
| Armistice Capital | $9,079 | 19.11% | new |
| Virtu Financial | $5,000 | 10.52% | new |
| XTX Topco | $4,235 | 8.91% | −30.27% |
| Rhumbline | $3,417 | 7.19% | +619.54% |
| Manager | Value | % base | |
|---|---|---|---|
| Citadel | $15,726 | 33.10% | new |
| Armistice Capital | $9,079 | 19.11% | new |
| Virtu Financial | $5,000 | 10.52% | new |
| XTX Topco | $4,235 | 8.91% | −30.27% |
| Rhumbline | $3,417 | 7.19% | +619.54% |
Largest filed tie
—
—
—